Immune Pharmaceuticals Inc.
IMNP
IMNP was delisted on the 25th of July, 2018.
12 hedge funds and large institutions have $565K invested in Immune Pharmaceuticals Inc. in 2015 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 12 → 12 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
1% less capital invested
Capital invested by funds: $573K → $565K (-$8K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$61.5K |
| 2 |
BIM
BlackRock Investment Management
Wilmington,
Delaware
|
+$6.4K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$3.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$100K |
| 2 |
ARTA
A.R.T. Advisors
New York
|
-$18K |
| 3 |
Goldman Sachs
New York
|
-$10.3K |
| 4 |
Citigroup
New York
|
-$355 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PRCM
1
Pine River Capital Management
Minnetonka,
Minnesota
| $295K | – | – | – |
|
|
EEG
2
E.E. Geduld
| $68K | – | – | – |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $60K | +$61.5K | +1,558 | New |
|
|
4
Goldman Sachs
New York
| $55K | -$10.3K | -260 | -15% |
|
|
IFS
5
Ifrah Financial Services
Little Rock,
Arkansas
| $42K | – | – | – |
|
|
BPCE
6
Bank Pictet & Cie (Europe)
Frankfurt Am Main,
Germany
| $25K | – | – | – |
|
|
BIT
7
BlackRock Institutional Trust
San Francisco,
California
| $8K | – | – | – |
|
|
BIM
8
BlackRock Investment Management
Wilmington,
Delaware
| $6K | +$6.4K | +162 | New |
|
|
9
UBS Group
Zurich,
Switzerland
| $4K | +$3.2K | +81 | +270% |
|
|
LTFS
10
Ladenburg Thalmann Financial Services
Miami,
Florida
| $2K | – | – | – |
|
|
VKH
11
Virtu KCG Holdings
New York
| – | -$100K | -2,780 | Closed |
|
|
ARTA
12
A.R.T. Advisors
New York
| – | -$18K | -520 | Closed |
|
|
13
Citigroup
New York
| – | -$355 | -9 | -69% |
|
IMNP Hedge Fund Activity: Q2 2015 in Review
12 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Immune Pharmaceuticals Inc. (IMNP) for Q2 2015, worth a combined $565K — down 1.4% from $573K a quarter earlier.
Fund positioning in IMNP was balanced in Q2 2015: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 2 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $61.5K. The largest seller was Virtu KCG Holdings, exiting entirely with an estimated $100K sold.
- 12 institutional investors held Immune Pharmaceuticals Inc. (IMNP) as of Q2 2015, unchanged from Q1 2015.
- Funds reported $565K of Immune Pharmaceuticals Inc. stock for Q2 2015, down 1.4% quarter-over-quarter.
- 2 funds opened new Immune Pharmaceuticals Inc. positions in Q2 2015 and 2 closed out, a net change of 0 holders.
- The largest Immune Pharmaceuticals Inc. buyer in Q2 2015 was Vanguard Group, an estimated $61.5K added.
- The largest Immune Pharmaceuticals Inc. seller in Q2 2015 was Virtu KCG Holdings, an estimated $100K sold.
Based on aggregated 13F filings for Q2 2015.